PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

ABT vs. OGN

Last updated Feb 24, 2024

Compare and contrast key facts about Abbott Laboratories (ABT) and Organon & Co. (OGN).

Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ABT or OGN.

Key characteristics


ABTOGN
YTD Return9.06%30.26%
1Y Return18.86%-25.08%
Sharpe Ratio0.95-0.60
Daily Std Dev19.67%42.59%
Max Drawdown-45.62%-69.56%
Current Drawdown-11.99%-47.79%

Fundamentals


ABTOGN
Market Cap$207.28B$3.61M
EPS$3.26$0.43
PE Ratio36.640.08
PEG Ratio28.860.00
Revenue (TTM)$40.11B$2.46B
Gross Profit (TTM)$24.58B$334.14M
EBITDA (TTM)$10.46B$95.42M

Correlation

0.40
-1.001.00

The correlation between ABT and OGN is 0.40, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

ABT vs. OGN - Performance Comparison

In the year-to-date period, ABT achieves a 9.06% return, which is significantly lower than OGN's 30.26% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2024February
15.82%
-11.91%
ABT
OGN

Compare stocks, funds, or ETFs


Abbott Laboratories

Organon & Co.

ABT vs. OGN - Dividend Comparison

ABT's dividend yield for the trailing twelve months is around 1.74%, less than OGN's 7.57% yield.


TTM20232022202120202019201820172016201520142013
ABT
Abbott Laboratories
1.74%1.85%1.71%1.28%1.32%1.47%1.55%1.86%2.71%2.14%1.95%1.46%
OGN
Organon & Co.
6.05%7.77%4.01%1.84%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

ABT vs. OGN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Abbott Laboratories (ABT) and Organon & Co. (OGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABT
Abbott Laboratories
0.95
OGN
Organon & Co.
-0.60

ABT vs. OGN - Sharpe Ratio Comparison

The current ABT Sharpe Ratio is 0.95, which is higher than the OGN Sharpe Ratio of -0.60. The chart below compares the 12-month rolling Sharpe Ratio of ABT and OGN.


Rolling 12-month Sharpe Ratio-1.50-1.00-0.500.000.501.00SeptemberOctoberNovemberDecember2024February
0.95
-0.60
ABT
OGN

ABT vs. OGN - Drawdown Comparison

The maximum ABT drawdown since its inception was -45.62%, smaller than the maximum OGN drawdown of -69.56%. The drawdown chart below compares losses from any high point along the way for ABT and OGN


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%SeptemberOctoberNovemberDecember2024February
-11.99%
-47.79%
ABT
OGN

ABT vs. OGN - Volatility Comparison

The current volatility for Abbott Laboratories (ABT) is 5.06%, while Organon & Co. (OGN) has a volatility of 17.62%. This indicates that ABT experiences smaller price fluctuations and is considered to be less risky than OGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2024February
5.06%
17.62%
ABT
OGN